Overview

• A study published in Blood Advances found that statin use is associated with a 61% reduction in cancer-specific mortality in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• Statin users also experienced a 38% reduction in all-cause mortality and a 26% lower risk of disease progression, based on an analysis of 1,467 patients across four international clinical trials from 2012 to 2019.
• The findings remained robust after adjusting for factors such as age, sex, disease severity, co-existing illnesses, and treatment regimens.
• No increase in severe or life-threatening adverse events was observed among statin users, underscoring their safety as a potential adjunct therapy.
• Researchers are calling for laboratory studies and randomized clinical trials to confirm causality and explore the mechanisms behind statins' potential anti-cancer effects.